Navigation Links
Study in Cell by Magen BioSciences Co-Founder David E. Fisher,Identifies New Roles in Skin Cancer Prevention for Key Tumor,Suppressor Protein

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Mar 8, 2007 - Magen BioSciences, Inc., a specialty dermatology company, today announced the publication of a paper in the March 9, 2007 issue of the journal Cell by its co-founder and board member, David E. Fisher, M.D., Ph.D., that identifies two new functions for an important protein, p53, in the pigmentation of skin. Fisher's study shows that in addition to its function as a tumor suppressor in other cancers in the body, p53 also plays a key role in prompting the skin to tan in response to ultraviolet light from the sun. By promoting tanning, p53 deters the development of the skin cancer melanoma, which is increasing in incidence faster than any other cancer in the world.

Fisher's research also shows that p53 causes the production of an endorphin after ultraviolet exposure, and this may modulate sensation in the skin in a manner that influences behaviors, possibly including sun-seeking behaviors.

For Magen BioSciences, the study in Cell provides important proof of concept for the company's approach to identify and develop therapeutic treatments for pigmentation disorders.

"We know that people who tan easily or have dark pigmentation are far less likely to develop melanoma," said David Fisher, with the Dana-Faber Cancer Institute. "This study suggests that p53, one of the best-known tumor-suppressor proteins in our body, goes into action when skin cells experience UV exposure, prompting the skin to tan as a defensive mechanism against DNA damage and at the same time creating endorphins that may alter sensation or even behavior."

"Dr. Fisher's discovery of this new function for a well-known protein sheds new light on the mechanism and function of tanning," said Brian Gallagher, Ph.D., Magen's president and chief executive officer. "This discovery will help Magen BioSciences identify lead compounds and develop therapeutic treatments for disfiguring dermato
'"/>




Page: 1 2

Related medicine technology :

1. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
2. Clinical Study Shows Regenecare Relieves Pain and Itching of Skin Rashes Caused by Widely Used Cancer Drugs
3. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
4. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
5. Reaction to Avandia Warnings Stronger Among Internists Than Endocrinologists, According to Study by GfK Market Measures
6. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
8. Protox Announces Positive Clinical Data from Prostate Cancer Study
9. International ENDORSE Study Shows That the Majority of Hospitalized Patients Surveyed are at Risk for VTE and Many do not Receive Recommended VTE prophylaxis
10. New Study Shows That Extending Prophylaxis With Clexane / Lovenox (enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10 Days for Reducing the Risk of Venous Thromboembolism (VTE) in Acutely ill Medical Patients With Reduced Mobility
11. Genzyme Announces Data from First Phase 3 Study of Tolevamer in Patients with C. difficile Associated Diarrhea
Post Your Comments:
(Date:10/20/2014)... 2014 Norgine B.V. today announced ... volume bowel preparation, NER1006, presented at the 79 th ... Gastroenterology (ACG), Philadelphia, PA , has ... and co-primary endpoint of cleansing success. The study demonstrated ... ® in screening colonoscopy patients. [1] ...
(Date:10/19/2014)... -- Henry Schein, Inc. (NASDAQ: HSIC ), the ... to office-based dental, animal health and medical practitioners, announced ... Inc., a leading full-service provider of dental consumables, implants ... into Japan , the world,s 2 ... the number of countries in which the Company operates. ...
(Date:10/17/2014)... , Oct. 17, 2014  Training market researchers ... critical success factor in today,s highly competitive global ... research organizations that effectively and efficiently produce high ... service area. Effective training programs ... earn recognition from internal clients by developing analysts ...
Breaking Medicine Technology:Positive Results from Phase II Data Show NER1006 Achieves High Quality Bowel Cleansing Efficacy 2Henry Schein Enters Japan With Investment in Iwase Dental Supply 2Henry Schein Enters Japan With Investment in Iwase Dental Supply 3Henry Schein Enters Japan With Investment in Iwase Dental Supply 4Henry Schein Enters Japan With Investment in Iwase Dental Supply 5Effective Training Programs for Market Research Groups can Boost Overall Organizational Success 2
... , MALVERN, ... a privately held biopharmaceutical company, and Cephalon, Inc. (Nasdaq: ... trial for CINQUIL(TM) (reslizumab) as a treatment for pediatric eosinophilic ... in the co-primary endpoints of changes in esophageal eosinophil levels ...
... , WAPPINGERS ... Medical, in alliance with the American Academy of Pediatrics (AAP), ... with Laerdal,s SimNewB (TM) neonatal patient simulator. SimNewB is designed ... to facilitate training for treatment of other critical medical conditions ...
Cached Medicine Technology:Ception Therapeutics and Cephalon Provide Initial Results of a Phase IIb/III Study of CINQUIL in Pediatric Eosinophilic Esophagitis 2Ception Therapeutics and Cephalon Provide Initial Results of a Phase IIb/III Study of CINQUIL in Pediatric Eosinophilic Esophagitis 3Ception Therapeutics and Cephalon Provide Initial Results of a Phase IIb/III Study of CINQUIL in Pediatric Eosinophilic Esophagitis 4Ception Therapeutics and Cephalon Provide Initial Results of a Phase IIb/III Study of CINQUIL in Pediatric Eosinophilic Esophagitis 5Neonatal Scenarios Developed in Partnership with the American Academy of Pediatrics (AAP), Utilize the NRP Curriculum to Advance Newborn Care 2Neonatal Scenarios Developed in Partnership with the American Academy of Pediatrics (AAP), Utilize the NRP Curriculum to Advance Newborn Care 3
(Date:10/20/2014)... 20, 2014 AttorneyOne.com, a recognized authority on ... from the FDA on Sit and Slim II . ... to purchase or use Sit and Slim II because it ... is promoted as weight loss product on various websites and ... market in 2010 for safety reasons, can significantly increase blood ...
(Date:10/20/2014)... October 20, 2014 Rockynol Retirement ... Center on Oct. 14. The $11 million project will ... and a cooked-to-order kitchen with full-service restaurant style dining. ... choice for first class Assisted Living apartments,” said Kara ... deserve the highest quality of care and this investment ...
(Date:10/20/2014)... (PRWEB) October 20, 2014 Based ... are the only imaging assays capable of determining ... single test.  With these three dimensions of high-resolution ... to detect the widest range of disease-causing genetic ... missed by other genomic tools, including today’s advanced ...
(Date:10/20/2014)... Final Cut Pro X Plugin developers from Pixel ... for FCPX filmmakers . , “Fun, cool, and simple ... theme” Says Christina Austin, CEO of Pixel Film Studios. “It ... Citrus comes with all the tools needed for a ... for added style, a title screen for an introduction, two ...
(Date:10/20/2014)... 2014 It’s hard to imagine what it’s ... vulnerable children around the world, it’s a reality. And while ... children are forced to walk barefoot on rocky terrain or ... play with their friends. , Buckner International's Shoes ... Radio in October to encourage support for Air1 and ...
Breaking Medicine News(10 mins):Health News:FDA Advises Not to Use Sit and Slim II: AttorneyOne Monitors and Keeps Consumers Informed 2Health News:Rockynol Retirement Community Expands Assisted Living Center 2Health News:KromaTiD Launches Genome Screening and Discovery Services 2Health News:KromaTiD Launches Genome Screening and Discovery Services 3Health News:Today Pixel Film Studios Announced the Release of the Citrus theme for Final Cut Pro X 2Health News:Buckner Shoes for Orphan Souls® Garners Support from Air1 Radio 2Health News:Buckner Shoes for Orphan Souls® Garners Support from Air1 Radio 3
... Paragon Medsystems unveiled their new corporate identity at ... Effective immediately, the company name will be California MedTech.The ... providing turnkey development and manufacturing services to the medical ... focus on the medtech sector, as well as our ...
... Hepatocellular carcinoma (HCC) is a highly aggressive form of ... cancers worldwide. Devanand Sarkar and colleagues, at Virginia Commonwealth ... gene that is expressed at high levels in human ... HCC progression. They therefore suggest that targeting this gene ...
... the two might be genetic, researchers say , , MONDAY, Feb. ... melanoma are twice as likely to develop Parkinson,s disease, a ... are not clear, other studies have shown that people with ... "For people with a family member with melanoma, they may ...
... patients who undergo surgery at teaching-intensive hospitals have ... these better survival rates apparently occur in white ... in surgical outcomes for patients in teaching-intensive hospitals ... from other studies," said study leader Jeffrey H. ...
... improved expertise after surgery, but reasons unclear, study finds ... are less likely to die of post-surgery complications at ... doesn,t apply to black patients, a U.S. study. finds. ... at The Children,s Hospital of Philadelphia and the University ...
... technological breakthroughsCLEVELAND, Feb. 16 NorTech, in partnership ... to announce the winners of its annual Innovation ... Northeast Ohio innovators who are impacting the lives ... world. This year, a distinguished panel of judges ...
Cached Medicine News:Health News:Paragon Medsystems Becomes California MedTech 2Health News:Family History of Melanoma Doubles Parkinson's Risk 2Health News:White Patients Benefit More Than Blacks in Surviving Surgical Complications at Teaching Hospitals 2Health News:White Patients Benefit More Than Blacks in Surviving Surgical Complications at Teaching Hospitals 3Health News:Teaching Hospitals' Post-Op Gains Not Extended to Blacks 2Health News:NorTech, Crain's Cleveland Business Honor 2009 Innovation Award Winners 2Health News:NorTech, Crain's Cleveland Business Honor 2009 Innovation Award Winners 3Health News:NorTech, Crain's Cleveland Business Honor 2009 Innovation Award Winners 4Health News:NorTech, Crain's Cleveland Business Honor 2009 Innovation Award Winners 5
... The compact Allegra X-22 Series is up to 10 ... a library of 11 rotors, the Allegra X-22 Series ... Features: Only 18 inches / 46 cm ... 22,065 x g 3 different ways to Spin ...
... Optimal for Subcellular Fractionation, ... x g (30,000 rpm) with ... from 0.25 up to 85 ... 2° C to 40° C ...
... to accommodate over 55 centrifuge tubes, bottles, ... labile samples. Incorporating the latest technology, these ... quick cooling from 22 C to 4 ... brushless motor, low pitch 62 dBA quiet ...
Inquire...
Medicine Products: